Navigation Links
Astellas Expands Leadership Team With Senior Vice President of Corporate Strategy and Government Affairs
Date:8/15/2011

DEERFIELD, Ill., Aug. 15, 2011 /PRNewswire/ -- Astellas US, LLC ("Astellas") recently named Percival Barretto-Ko as Senior Vice President, Corporate Strategy and Government Affairs, a new position added to the company's leadership team.  Reporting to President and CEO Masao Yoshida, Barretto-Ko will be responsible for corporate planning, business development, government policy and external affairs and state government affairs.

"This realignment brings key strategic functions closer together at the corporate level," Yoshida said.  "Percival has an outstanding track record both in the pharmaceutical industry and at Astellas' European operations.  He will be a great addition to our senior management team."

Barretto-Ko will move from the position of executive director, corporate strategy and communications at Astellas Pharma Europe Ltd.  While there, he led the global launch of Astellas' new pipeline drug, Advagraf® (tacrolimus prolonged release) in 20 countries. He was promoted to lead the organization's corporate planning function and ultimately directed corporate strategy, corporate planning, corporate communications, crisis management and corporate social responsibility. Prior to joining Astellas, he held increasingly more senior marketing and sales positions with the Roche Group in the United States and United Kingdom. Barretto-Ko earned his undergraduate degree from Cornell University, an MBA from Yale School of Management, and an MS from MIT Sloan School of Management, where he recently served as a Sloan Fellow for Innovation and Global Leadership.

About Astellas

Astellas US LLC, located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas US LLC, please visit our website at www.astellas.us or follow us on Twitter at www.Twitter.com/AstellasUS.


'/>"/>
SOURCE Astellas US, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise
2. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
3. Astellas to Review Strategic Business Alternatives for Prosidion Subsidiary
4. Reportlinker Adds Astellas Pharma Inc.: PharmaVitae Profile
5. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
6. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
7. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
8. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
9. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
10. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
11. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):